bicalutamide has been researched along with tamoxifen in 34 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (5.88) | 18.2507 |
| 2000's | 12 (35.29) | 29.6817 |
| 2010's | 18 (52.94) | 24.3611 |
| 2020's | 2 (5.88) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Glen, RC; Lowe, R; Mitchell, JB | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Azizi, B; Doyle, DF; Gryder, BE; Johnson, KA; Oyelere, AK; Patil, V; Raftery, ED; Rice, M; Rood, MK; Yao, LP | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Wakeling, AE | 1 |
| Richie, JP | 1 |
| Battaglia, M; Bertaccini, A; Boccardo, F; Comeri, G; Conti, G; Di Tonno, P; Durand, F; Ferraris, V; Galassi, P; Macchiarella, A; Manganelli, A; Martorana, G; Montefiore, F; Muscas, G; Potenzoni, D; Rubagotti, A; Selvaggi, FP; Siragusa, A; Zattoni, F | 1 |
| Gallo, J; Morris, T; Saltzstein, D; Sieber, P | 1 |
| Boccardo, F; Conti, G; Del Monaco, D; Manganelli, A; Potenzoni, D; Rubagotti, A | 1 |
| Autorino, R; Bianco, AR; D'Armiento, M; Damiano, R; De Placido, S; De Sio, M; Di Lorenzo, G; Gallo, A; Gallo, L; Perdonà, S; Pingitore, D | 1 |
| Thönnessen, D; Wenz, F | 1 |
| Autorino, R; D'Armiento, M; Damiano, R; De Placido, S; De Sio, M; Di Lorenzo, G; Gallo, A; Gallo, L; Perdonà, S; Pingitore, D | 1 |
| Andersen, M; Armstrong, J; Egerdie, B; Fradet, Y; Morris, T; Nachabe, M; Navani, S; Tammela, TL | 1 |
| Van Poppel, H | 1 |
| Dawkins, GP; Harris, JP; Nuttall, MC | 1 |
| Sieber, PR | 1 |
| Aragona, F; Bedognetti, D; Boccardo, F; Canclini, L; Conti, G; Cortellini, P; De Cobelli, O; Di Tonno, P; Francesca, F; Gallucci, M; Lapini, A; Martorana, G; Rubagotti, A | 1 |
| Balbi, C; Barboro, P; Boccardo, F; Ferrari, N; Repaci, E; Rubagotti, A | 1 |
| Allegro, R; Altieri, V; De Grande, G; Ferraù, F; Gebbia, V; Mazza, R; Melloni, D; Morgia, G; Nicolosi, F; Serretta, V | 1 |
| Garcia, PL; Gomes, FP | 1 |
| Argellati, F; Boccardo, F; Mangerini, R; Pfeffer, U | 1 |
| Alfaro, IE; Bernales, S; Cittelly, DM; Cochrane, DR; D'Amato, NC; Edgerton, SM; Elias, AD; Gómez, F; Guerrero, J; Howe, EN; Jacobsen, BM; Jean, A; Jedlicka, P; McCullagh, E; Medicherla, S; Protter, AA; Richer, JK; Spoelstra, NS; Thor, AD; Torkko, KC | 1 |
| Bevan, CL; Brooke, GN; Fioretti, FM; Sita-Lumsden, A | 1 |
| Baumgarten, L; Dabaja, AA | 1 |
| Beijnen, JH; de Jong, KAM; de Vries, N; Rosing, H; van Nuland, M; Venekamp, N | 1 |
| Aebersold, DM; Albrecht, C; Böhmer, D; Flentje, M; Ganswindt, U; Ghadjar, P; Höcht, S; Hölscher, T; Müller, AC; Niehoff, P; Pinkawa, M; Sedlmayer, F; Wiegel, T; Zips, D | 1 |
| Cao, J; Du, X; Liang, Z; Peng, Y; Shi, J; Tian, L; Yang, K; Zhang, J | 1 |
7 review(s) available for bicalutamide and tamoxifen
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Steroid antagonists as nuclear receptor blockers.
Topics: Androgen Antagonists; Anilides; Animals; Estradiol; Estrogen Antagonists; Estrogens; Humans; Mifepristone; Nitriles; Polyunsaturated Alkamides; Rats; Receptors, Estrogen; Tamoxifen; Tosyl Compounds | 1992 |
Anti-androgens and other hormonal therapies for prostate cancer.
Topics: Androgen Antagonists; Androgens; Anilides; Biomarkers, Tumor; Flutamide; Humans; Male; Neoplasms, Hormone-Dependent; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Tamoxifen; Tosyl Compounds | 1999 |
Treatment of bicalutamide-induced breast events.
Topics: Androgen Antagonists; Anilides; Clinical Trials as Topic; Estrogen Receptor Modulators; Gynecomastia; Humans; Male; Nitriles; Pain; Pain Management; Prostatic Neoplasms; Tamoxifen; Tosyl Compounds | 2007 |
Revising the role of the androgen receptor in breast cancer.
Topics: Abiraterone Acetate; Androgen Antagonists; Androgens; Androstadienes; Anilides; Estrogen Antagonists; Female; Humans; Nitriles; Receptors, Androgen; Receptors, Estrogen; Signal Transduction; Steroid 17-alpha-Hydroxylase; Tamoxifen; Tosyl Compounds; Triple Negative Breast Neoplasms | 2014 |
Diagnosis and Management of Gynecomastia for Urologists.
Topics: Androgen Antagonists; Anilides; Estrogen Antagonists; Gynecomastia; Humans; Male; Nitriles; Prostatic Neoplasms; Tamoxifen; Tosyl Compounds | 2018 |
Treatment strategies to prevent and reduce gynecomastia and/or breast pain caused by antiandrogen therapy for prostate cancer : Statement from the DEGRO working group prostate cancer.
Topics: Adenocarcinoma; Anastrozole; Androgen Antagonists; Androgens; Anilides; Antineoplastic Agents, Hormonal; Dizziness; Dose Fractionation, Radiation; Drug Administration Schedule; Estrogen Receptor Modulators; Flushing; Gynecomastia; Humans; Male; Mastodynia; Meta-Analysis as Topic; Neoplasms, Hormone-Dependent; Nitriles; Off-Label Use; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Tamoxifen; Tosyl Compounds | 2020 |
8 trial(s) available for bicalutamide and tamoxifen
| Article | Year |
|---|---|
Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Anilides; Breast Diseases; Double-Blind Method; Gynecomastia; Humans; Male; Middle Aged; Nitriles; Pain; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Tamoxifen; Testosterone; Tosyl Compounds; Triazoles | 2005 |
Prevention and management of bicalutamide-induced gynecomastia and breast pain: randomized endocrinologic and clinical studies with tamoxifen and anastrozole.
Topics: Aged; Aged, 80 and over; Anastrozole; Anilides; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Diseases; Double-Blind Method; Gynecomastia; Humans; Male; Middle Aged; Nitriles; Pain; Placebos; Prostatic Neoplasms; Tamoxifen; Testosterone; Tosyl Compounds; Treatment Outcome; Triazoles | 2005 |
Exploratory study of drug plasma levels during bicalutamide 150 mg therapy co-administered with tamoxifen or anastrozole for prophylaxis of gynecomastia and breast pain in men with prostate cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Chromatography, High Pressure Liquid; Double-Blind Method; Drug Interactions; Gynecomastia; Humans; Male; Middle Aged; Nitriles; Pain; Prostatic Neoplasms; Tamoxifen; Tosyl Compounds; Triazoles | 2005 |
Efficacy of tamoxifen and radiotherapy for prevention and treatment of gynaecomastia and breast pain caused by bicalutamide in prostate cancer: a randomised controlled trial.
Topics: Aged; Androgen Antagonists; Anilides; Antineoplastic Agents; Combined Modality Therapy; Disease-Free Survival; Estrogen Antagonists; Gynecomastia; Humans; Male; Middle Aged; Nitriles; Pain; Prostatic Neoplasms; Tamoxifen; Tosyl Compounds | 2005 |
Gynecomastia and breast pain induced by adjuvant therapy with bicalutamide after radical prostatectomy in patients with prostate cancer: the role of tamoxifen and radiotherapy.
Topics: Aged; Androgen Antagonists; Androgens; Anilides; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Chemotherapy, Adjuvant; Disease-Free Survival; Estrogen Receptor Modulators; Follow-Up Studies; Gynecomastia; Humans; Male; Middle Aged; Nitriles; Pain; Penile Erection; Prospective Studies; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Quality of Life; Radiotherapy, Adjuvant; Severity of Illness Index; Tamoxifen; Testosterone; Time Factors; Tosyl Compounds; Treatment Outcome | 2005 |
Tamoxifen as prophylaxis for prevention of gynaecomastia and breast pain associated with bicalutamide 150 mg monotherapy in patients with prostate cancer: a randomised, placebo-controlled, dose-response study.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Dose-Response Relationship, Drug; Double-Blind Method; Estrogen Antagonists; Follow-Up Studies; Gynecomastia; Humans; Incidence; Male; Middle Aged; Neoplasm Staging; Nitriles; Pain; Prostatic Neoplasms; Tamoxifen; Tosyl Compounds; Treatment Outcome | 2007 |
An open, randomised, multicentre, phase 3 trial comparing the efficacy of two tamoxifen schedules in preventing gynaecomastia induced by bicalutamide monotherapy in prostate cancer patients.
Topics: Aged; Anilides; Antineoplastic Agents; Drug Administration Schedule; Estrogen Antagonists; Gynecomastia; Humans; Male; Middle Aged; Nitriles; Prostatic Neoplasms; Tamoxifen; Tosyl Compounds | 2010 |
A randomized trial comparing tamoxifen therapy vs. tamoxifen prophylaxis in bicalutamide-induced gynecomastia.
Topics: Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Chemotherapy, Adjuvant; Estrogen Antagonists; Gynecomastia; Humans; Male; Middle Aged; Nitriles; Prostatic Neoplasms; Statistics, Nonparametric; Tamoxifen; Tosyl Compounds; Treatment Outcome | 2012 |
19 other study(ies) available for bicalutamide and tamoxifen
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Identifying off-target effects and hidden phenotypes of drugs in human cells.
Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship | 2006 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
Predicting phospholipidosis using machine learning.
Topics: Animals; Artificial Intelligence; Databases, Factual; Drug Discovery; Humans; Lipidoses; Models, Biological; Phospholipids; Support Vector Machine | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Histone deacetylase inhibitors equipped with estrogen receptor modulation activity.
Topics: Animals; Antineoplastic Agents; Cells, Cultured; Drug Discovery; Estrogen Receptor Modulators; Histone Deacetylase Inhibitors; Humans; Molecular Docking Simulation; Receptors, Estrogen; Structure-Activity Relationship | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
Radiotherapeutic prophylaxis of gynecomastia.
Topics: Anastrozole; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Gynecomastia; Humans; Male; Nitriles; Pain; Prostatic Neoplasms; Quality of Life; Tamoxifen; Tosyl Compounds; Triazoles | 2005 |
Editorial comment on: Tamoxifen as prophylaxis for prevention of gynaecomastia and breast pain associated with bicalutamide 150 mg monotherapy in patients with prostate cancer: a randomised, placebo-controlled, dose-response study.
Topics: Androgen Antagonists; Anilides; Dose-Response Relationship, Drug; Estrogen Antagonists; Follow-Up Studies; Gynecomastia; Humans; Male; Nitriles; Pain; Prostatic Neoplasms; Tamoxifen; Tosyl Compounds; Treatment Outcome | 2007 |
The role of tamoxifen in reducing bicalutamide-induced gynaecomastia and breast pain.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Gynecomastia; Humans; Male; Nitriles; Pain; Prostatic Neoplasms; Tamoxifen; Tosyl Compounds; Treatment Outcome | 2007 |
Androgen receptor and heterogeneous nuclear ribonucleoprotein K colocalize in the nucleoplasm and are modulated by bicalutamide and 4-hydroxy-tamoxifen in prostatic cancer cell lines.
Topics: Androgen Antagonists; Anilides; Cell Line, Tumor; Cell Nucleus; Cell Survival; Estrogen Antagonists; Heterogeneous-Nuclear Ribonucleoprotein K; Humans; Male; Nitriles; Phosphorylation; Prostate-Specific Antigen; Prostatic Neoplasms; Receptors, Androgen; Tamoxifen; Tosyl Compounds | 2011 |
Development and validation of a simple and sensitive high performance liquid chromatographic method for the simultaneous determination of anastrozole, bicalutamide, tamoxifen, and their synthetic impurities.
Topics: Analysis of Variance; Anastrozole; Anilides; Calibration; Chromatography, High Pressure Liquid; Limit of Detection; Nitriles; Reproducibility of Results; Tamoxifen; Tosyl Compounds; Triazoles | 2012 |
Effects of bicalutamide and 4OH-tamoxifen on androgen-regulated gene expression in the LNCaP cell line.
Topics: Androgens; Anilides; Antineoplastic Combined Chemotherapy Protocols; Cell Growth Processes; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Humans; Kallikreins; Male; Neoplasms, Hormone-Dependent; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Tamoxifen; Tosyl Compounds | 2012 |
Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide.
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Anilides; Animals; Antineoplastic Agents, Hormonal; Apoptosis; Benzamides; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Disease-Free Survival; Estrogen Receptor alpha; Female; Humans; MCF-7 Cells; Mice; Middle Aged; Neoplasm Transplantation; Nitriles; Phenylthiohydantoin; Receptors, Androgen; Signal Transduction; Tamoxifen; Tosyl Compounds; Transplantation, Heterologous | 2014 |
Development and validation of an UPLC-MS/MS method for the therapeutic drug monitoring of oral anti-hormonal drugs in oncology.
Topics: Administration, Oral; Anastrozole; Androstadienes; Androstenes; Anilides; Antineoplastic Agents, Hormonal; Benzamides; Chromatography, High Pressure Liquid; Drug Monitoring; Humans; Nitriles; Phenylthiohydantoin; Tamoxifen; Tandem Mass Spectrometry; Tosyl Compounds | 2019 |
The ERα-NRF2 signalling axis promotes bicalutamide resistance in prostate cancer.
Topics: Cell Line, Tumor; Estrogen Receptor alpha; Estrogens; Gene Expression Regulation, Neoplastic; Humans; Male; NF-E2-Related Factor 2; Prostatic Neoplasms, Castration-Resistant; Tamoxifen | 2022 |